Drug Trial Radar · NCT07798947
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung cancer.
Conditions
- Limited-stage Small-cell Lung Cancer
Interventions
SHR-7787 InjectionDrug
SHR-7787 injection.
SHR-1316Drug
SHR-1316 (Adebrelimab) Injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: Approximately 3 weeks
- Incidence and severity of serious adverse events (SAEs)Time frame: Approximately 3 weeks
- Progression-Free Survival (PFS)Time frame: Approximately 16 months
- Progression-Free Survival (PFS)Time frame: Approximately 16 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.